MedTrace Logo

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

NCT00771147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2012-06-15

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

Conditions

  • Carcinoma, Renal Cell
  • Carcinoma, Renal Cell (Advanced)

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Completion
2010-11-30

Countries

  • Belgium

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771147 on ClinicalTrials.gov